Sources | Names Used |
---|---|
CTRPv2 | navitoclax:gemcitabine (1:1 mol/mol) |
PharmacoGx | navitoclax:gemcitabine (1:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | CALU | CTRPv2 | pan-cancer | AAC | -0.21 | 8e-07 |
mRNA | CD151 | CTRPv2 | pan-cancer | AAC | -0.21 | 4e-07 |
mRNA | SLC39A13 | CTRPv2 | pan-cancer | AAC | -0.2 | 4e-07 |
mRNA | EHD2 | CTRPv2 | pan-cancer | AAC | -0.2 | 8e-08 |
mRNA | CTSA | CTRPv2 | pan-cancer | AAC | -0.2 | 1e-07 |
mRNA | SERINC3 | CTRPv2 | pan-cancer | AAC | -0.2 | 3e-08 |
mRNA | PPIC | CTRPv2 | pan-cancer | AAC | -0.2 | 1e-06 |
mRNA | TMED7-TICAM2 | CTRPv2 | pan-cancer | AAC | -0.2 | 4e-07 |
mRNA | RTFDC1 | CTRPv2 | pan-cancer | AAC | -0.2 | 4e-08 |
mRNA | PCYOX1 | CTRPv2 | pan-cancer | AAC | -0.2 | 7e-07 |